The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Lilly, Pfizer, Seagen, Daichii Sankyo, Novartis, Gilead, MSD, Astra Zeneca, Owkins
Travel, Accommodations, Expenses - Lilly, Pfizer, Novartis, Daiichi Sankyo, Amgen, AstraZeneca
Efficacy and safety of lurbinectedin (LUR) with irinotecan (IRI) in a phase 2 expansion cohort of patients (Pts) with synovial sarcoma (SS).
 
Gregory Michael Cote
No Relationships to Disclose
 
Javier Martin Broto
Leadership - Sarcoma Research Solutions SL
Consulting or Advisory Role - Amgen; Asofarma; Bayer; Boehringer Ingelheim; GlaxoSmithKline; Lilly; Novartis; PharmaMar; Roche; Tecnofarma
Speakers' Bureau - PharmaMar
Research Funding - Adaptimmune; Amgen (Inst); Arog (Inst); Ayala Pharmaceuticals (Inst); Bayer (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); CEBIOTEX (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Eisai; Eisai (Inst); FORMA Therapeutics (Inst); GlaxoSmithKline (Inst); Immix BioPharma (Inst); InhibRx (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Lixte Biotechnology (Inst); Nektar (Inst); Novartis; Novartis (Inst); Pfizer (Inst); PharmaMar; PharmaMar (Inst); Philogen (Inst); PTC Therapeutics (Inst); Rain Therapeutics (Inst); SpringWorks Therapeutics (Inst)
Expert Testimony - Novartis; PharmaMar
Travel, Accommodations, Expenses - Pfizer; PharmaMar
 
Sant P. Chawla
Stock and Other Ownership Interests - AADi; Cellestia Biotech; Counterpoint; Immix BioPharma
Honoraria - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Karyopharm Therapeutics; NKMax; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma; Tyme
Consulting or Advisory Role - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Karyopharm Therapeutics; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Speakers' Bureau - Amgen; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; Janssen; Karyopharm Therapeutics; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Research Funding - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Janssen; Karyopharm Therapeutics; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
 
Bruno Bockorny
Honoraria - BiolineRx; Enlivex Therapeutics Ltd
Consulting or Advisory Role - Blueprint Medicines
Research Funding - Agenus (Inst); Nanoview Diagnostics
Travel, Accommodations, Expenses - Agenus; ERYTECH Pharma
 
Alejandro Falcon Gonzalez
Consulting or Advisory Role - AstraZeneca; Pfizer; Roche/Genentech; Steve
Speakers' Bureau - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Eisai; Grunenthal; Lilly; Novartis; Pfizer; Roche/Genentech; Seagen
 
Antonio López Pousa
No Relationships to Disclose
 
Luis G. Paz-Ares
Leadership - ALTUM Sequencing; Stab Therapeutics
Stock and Other Ownership Interests - Altum Sequencing; Stab therapeutics
Honoraria - Amgen; AstraZeneca; Bayer; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline; Janssen; Lilly; Medscape; Merck Serono; Mirati Therapeutics; MSD; Novartis; Pfizer; PharmaMar; Regeneron; Roche/Genentech; Sanofi; Takeda
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; AstraZeneca; Bayer; BMS; GlaxoSmithKline; Janssen; Lilly; Merck; Mirati Therapeutics; MSD; Novartis; Pfizer; Pharmamar; Regeneron; Roche; Sanofi; Takeda
Speakers' Bureau - AstraZeneca; BMS; Lilly; Merck Serono; MSD Oncology; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); BMS (Inst); MSD (Inst); Pfizer (Inst); PharmaMar (Inst)
Other Relationship - Amgen (I); Ipsen (I); Merck (I); Novartis (I); Pfizer (I); Roche; Roche (I); Sanofi (I); SERVIER (I)
 
Benjamin Verret
No Relationships to Disclose
 
Sara Martinez
Employment - PharmaMar
 
Sonia Extremera
Employment - PharmaMar
 
Martin Cullell-Young
Employment - PharmaMar
 
Salvador Fudio
Employment - PharmaMar
 
Carmen Maria Kahatt
Employment - PharmaMar
Stock and Other Ownership Interests - PharmaMar
 
Ali Hassan Zeaiter
Employment - PharmaMar
Leadership - PharmaMar
Stock and Other Ownership Interests - PharmaMar; SERVIER
Honoraria - PharmaMar
Travel, Accommodations, Expenses - PharmaMar
 
Axel Le Cesne
Honoraria - Bayer, PharmaMar, Deciphera